loading
Precedente Chiudi:
$8.64
Aprire:
$8.67
Volume 24 ore:
342.33K
Relative Volume:
0.29
Capitalizzazione di mercato:
$1.10B
Reddito:
$175.51M
Utile/perdita netta:
$-78.02M
Rapporto P/E:
-16.69
EPS:
-0.53
Flusso di cassa netto:
$-34.18M
1 W Prestazione:
+12.89%
1M Prestazione:
+12.74%
6M Prestazione:
-3.61%
1 anno Prestazione:
+54.80%
Intervallo 1D:
Value
$8.585
$8.86
Intervallo di 1 settimana:
Value
$7.82
$8.85
Portata 52W:
Value
$5.195
$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name
Nome
Aurinia Pharmaceuticals Inc
Name
Telefono
250-744-2487
Name
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Name
Dipendente
300
Name
Cinguettio
@AuriniaPharma
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
AUPH's Discussions on Twitter

Confronta AUPH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AUPH
Aurinia Pharmaceuticals Inc
8.86 1.10B 175.51M -78.02M -34.18M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.88 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.41 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.58 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.75 28.51B 3.81B -644.79M -669.77M -6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-11-04 Downgrade Oppenheimer Outperform → Perform
2022-05-05 Ripresa Cantor Fitzgerald Overweight
2021-12-10 Aggiornamento Oppenheimer Perform → Outperform
2021-10-28 Downgrade Oppenheimer Outperform → Perform
2021-01-25 Reiterato H.C. Wainwright Buy
2020-11-03 Reiterato H.C. Wainwright Buy
2020-06-17 Iniziato BTIG Research Buy
2020-05-05 Iniziato Cowen Outperform
2020-01-10 Iniziato Jefferies Buy
2019-12-16 Reiterato H.C. Wainwright Buy
2018-03-16 Reiterato Cantor Fitzgerald Overweight
2018-02-08 Iniziato RBC Capital Mkts Outperform
2017-10-30 Reiterato H.C. Wainwright Buy
2017-05-18 Reiterato H.C. Wainwright Buy
2017-04-11 Iniziato Cantor Fitzgerald Overweight
2017-03-22 Reiterato FBR & Co. Outperform
2016-12-30 Reiterato H.C. Wainwright Buy
2016-08-17 Reiterato H.C. Wainwright Buy
2016-06-30 Iniziato H.C. Wainwright Buy
2015-05-08 Iniziato MLV & Co Buy
Mostra tutto

Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie

pulisher
Jun 15, 2025

With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance

Jun 15, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Bank of America Corp DE - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

As Edmonton biotech industry booms, Launa Aspeslet steps up to guide further success - Taproot Edmonton

Jun 10, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - mx.advfn.com

Jun 07, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Increases Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SDIG, AUPH and LICY - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

(AUPH) Trading Signals - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 06, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.27 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - InsuranceNewsNet

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Acquires 26,981 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Jun 06, 2025
pulisher
Jun 03, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of AUPH, IRNT and RSKD - ACCESS Newswire

Jun 03, 2025
pulisher
May 31, 2025

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - MSN

May 31, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Sells 14,003 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

May 31, 2025
pulisher
May 30, 2025

Is The Options Market Predicting A Spike In Aurinia Pharmaceuticals (AUPH) Stock? - Barchart.com

May 30, 2025
pulisher
May 28, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 28, 2025
pulisher
May 27, 2025

Nuveen Asset Management LLC Increases Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

May 27, 2025
pulisher
May 27, 2025

Cetera Investment Advisers Purchases 2,000 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

May 27, 2025
pulisher
May 27, 2025

(AUPH) Technical Data - news.stocktradersdaily.com

May 27, 2025
pulisher
May 26, 2025

Deutsche Bank AG Purchases 50,575 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

May 26, 2025
pulisher
May 23, 2025

US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert - Benzinga

May 23, 2025
pulisher
May 22, 2025

Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial R - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial Results | AUPH Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks

May 22, 2025
pulisher
May 19, 2025

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st

May 19, 2025
pulisher
May 19, 2025

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance

May 19, 2025
pulisher
May 16, 2025

Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Leerink Partnrs Has Positive Outlook of AUPH Q2 Earnings - Defense World

May 16, 2025
pulisher
May 15, 2025

Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks

May 15, 2025
pulisher
May 15, 2025

Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Aurinia Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Transcript : Aurinia Pharmaceuticals Inc.Shareholder/Analyst Call - marketscreener.com

May 15, 2025
pulisher
May 14, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN

May 14, 2025
pulisher
May 14, 2025

Aurinia Pharmaceuticals Financial Update and Strategic Growth Plans - Zenopa

May 14, 2025
pulisher
May 14, 2025

Aurinia Pharmaceuticals (AUPH) Reports Strong Q1 Earnings Beat - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Price T Rowe Associates Inc. MD Has $468,000 Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

May 14, 2025
pulisher
May 13, 2025

Aurinia outlines $250M–$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improves - MSN

May 13, 2025
pulisher
May 13, 2025

Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Company News for May 13, 2025 - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

May 12, 2025
pulisher
May 12, 2025

Document - SEC.gov

May 12, 2025
pulisher
May 12, 2025

Aurinia Pharmaceuticals Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks

May 12, 2025
pulisher
May 12, 2025

Aurinia: Q1 Earnings Snapshot - MySA

May 12, 2025
pulisher
May 12, 2025

Aurinia Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 12, 2025
pulisher
May 12, 2025

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance - Benzinga

May 12, 2025
pulisher
May 12, 2025

Leerink maintains Aurinia stock Outperform with $10 target - Investing.com

May 12, 2025
pulisher
May 12, 2025

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens - Investing.com India

May 12, 2025
pulisher
May 12, 2025

AUPH Reports Q1 Revenue Exceeding Expectations with Strong Outlo - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance

May 12, 2025

Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Aurinia Pharmaceuticals Inc Azioni (AUPH) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Greenleaf Peter
Chief Executive Officer
Mar 03 '25
Sale
8.00
195,593
1,564,744
1,953,892
Greenleaf Peter
Chief Executive Officer
Mar 04 '25
Sale
7.92
164,947
1,306,380
1,788,945
Keenan Greg
Chief Medical Officer
Mar 03 '25
Sale
8.00
12,239
97,912
161,789
Miller Joseph M
Chief Financial Officer
Mar 03 '25
Sale
8.00
61,859
494,872
633,515
Miller Joseph M
Chief Financial Officer
Mar 04 '25
Sale
7.92
56,154
444,740
577,361
Robertson Stephen P.
EVP, General Counsel
Mar 03 '25
Sale
8.00
64,872
518,976
566,883
Robertson Stephen P.
EVP, General Counsel
Mar 04 '25
Sale
7.92
57,607
456,247
509,276
Donley Matthew Maxwell
Chief Operating Officer
Mar 03 '25
Sale
8.00
65,902
527,216
739,456
Donley Matthew Maxwell
Chief Operating Officer
Mar 04 '25
Sale
7.92
58,991
467,209
680,465
TANG KEVIN
Director
Mar 04 '25
Buy
7.96
748,038
5,953,304
10,029,500
$20.45
price down icon 0.07%
$35.83
price down icon 0.13%
$21.04
price up icon 1.50%
$100.69
price up icon 1.62%
$106.62
price down icon 0.15%
biotechnology ONC
$244.34
price up icon 1.30%
Capitalizzazione:     |  Volume (24 ore):